Cargando…

Anti-tumor effects of Atractylenolide I on bladder cancer cells

BACKGROUND: Atractylenolide I (ATR-1), an active component of Rhizoma Atractylodis Macrocephalae, possesses cytotoxicity against various carcinomas. However, little is known about the effects of ATR-1on bladder cancer. In the present study, the anti-tumor activity of ATR-1 was examined on bladder ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Rui, Yu, Bi-xia, Chen, Jun-feng, Lv, Xiu-yi, Yan, Ze-jun, Cheng, Yue, Ma, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774103/ https://www.ncbi.nlm.nih.gov/pubmed/26931119 http://dx.doi.org/10.1186/s13046-016-0312-4

Ejemplares similares

Correction to: Anti-tumor effects of Atractylenolide I on bladder cancer cells
por: Yu, Rui, et al.
Publicado: (2018)

Anti-Tumor Effects of Atractylenolide-I on Human Ovarian Cancer Cells
por: Long, Fangyi, et al.
Publicado: (2017)

Anti-Tumor Activity of Atractylenolide I in Human Colon Adenocarcinoma In Vitro
por: Chan, Ka Woon Karen, et al.
Publicado: (2020)

UPLC-MS/MS of Atractylenolide I, Atractylenolide II, Atractylenolide III, and Atractyloside A in Rat Plasma after Oral Administration of Raw and Wheat Bran-Processed Atractylodis Rhizoma
por: Xu, Shizhao, et al.
Publicado: (2018)

Anti-Tumor Effects of Atractylenolide I Isolated from Atractylodes macrocephala in Human Lung Carcinoma Cell Lines
por: Liu, Huanyi, et al.
Publicado: (2013)

A Randomized Pilot Study of Atractylenolide I on Gastric Cancer Cachexia Patients
por: Liu, Yi, et al.
Publicado: (2008)

Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis
por: Chen, Jun-Feng, et al.
Publicado: (2017)

Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway
por: Huang, Jian-Ming, et al.
Publicado: (2014)

Atractylenolide I inhibits antibiotic-induced dysbiosis of the intestinal microbiome
por: Liu, Penglin, et al.
Publicado: (2021)

Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson’s Disease
por: More, Sandeep, et al.
Publicado: (2017)

Atractylenolide III ameliorates spinal cord injury in rats by modulating microglial/macrophage polarization
por: Xue, Meng‐Tong, et al.
Publicado: (2022)

Atractylenolide-I Sensitizes Triple-Negative Breast Cancer Cells to Paclitaxel by Blocking CTGF Expression and Fibroblast Activation
por: Wang, Meng, et al.
Publicado: (2021)

Atractylenolide I alleviates ischemia/reperfusion injury by preserving mitochondrial function and inhibiting caspase-3 activity
por: Sun, Caiqin, et al.
Publicado: (2021)

Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review
por: Xie, Zhiyi, et al.
Publicado: (2023)

P2X7 receptor involved in antitumor activity of atractylenolide I in human cervical cancer cells
por: Han, Yue, et al.
Publicado: (2022)

Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I
por: Zhang, Wan-li, et al.
Publicado: (2019)

The Anticancer Effects of Atractylenolide III Associate With the Downregulation of Jak3/Stat3-Dependent IDO Expression
por: Liu, Jun-bao, et al.
Publicado: (2020)

Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism
por: Liu, Wenjuan, et al.
Publicado: (2022)

Atractylenolide-1 alleviates gastroparesis in diabetic rats by activating the stem cell factor/c-kit signaling pathway
por: Li, Hui, et al.
Publicado: (2021)

Atractylenolide I Inhibits NLRP3 Inflammasome Activation in Colitis-Associated Colorectal Cancer via Suppressing Drp1-Mediated Mitochondrial Fission
por: Qin, Yao, et al.
Publicado: (2021)

Atractylenolide I Induces Apoptosis and Suppresses Glycolysis by Blocking the JAK2/STAT3 Signaling Pathway in Colorectal Cancer Cells
por: Li, Yanxi, et al.
Publicado: (2020)

Atractylenolide I ameliorates cancer cachexia through inhibiting biogenesis of IL‐6 and tumour‐derived extracellular vesicles
por: Fan, Meng, et al.
Publicado: (2022)

Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27
por: Qiao, Pengfei, et al.
Publicado: (2023)

Atractylenolide III ameliorated reflux esophagitis via PI3K/AKT/NF-κB/iNOS pathway in rats
por: Si, Xianzhe, et al.
Publicado: (2023)

Atractylenolide III alleviates sepsis-mediated lung injury via inhibition of FoxO1 and VNN1 protein
por: Fu, Ji-ding, et al.
Publicado: (2021)

Atractylenolide I Ameliorates Acetaminophen-Induced Acute Liver Injury via the TLR4/MAPKs/NF-κB Signaling Pathways
por: Du, Zhongyan, et al.
Publicado: (2022)

Atractylenolide I inhibited the development of malignant colorectal cancer cells and enhanced oxaliplatin sensitivity through the PDK1-FoxO1 axis
por: Sun, Ye, et al.
Publicado: (2022)

Atractylenolide III Attenuates Angiogenesis in Gastric Precancerous Lesions Through the Downregulation of Delta-Like Ligand 4
por: Gao, Ying, et al.
Publicado: (2022)

Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway
por: Li, Qian, et al.
Publicado: (2022)

Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro
por: Liu, Hong, et al.
Publicado: (2016)

Chemopreventive effects of atractylenolide II on mammary tumorigenesis via activating Nrf2-ARE pathway
por: Wang, Ting, et al.
Publicado: (2017)

Catalytic approach to in vivo metabolism of atractylenolide III using biomimetic iron–porphyrin complexes
por: Lim, Hanae, et al.
Publicado: (2021)

Atractylenolide II Inhibits Proliferation, Motility and Induces Apoptosis in Human Gastric Carcinoma Cell Lines HGC-27 and AGS
por: Tian, Shuang, et al.
Publicado: (2017)

Sinularin exerts anti-tumor effects against human renal cancer cells relies on the generation of ROS
por: Ma, Qi, et al.
Publicado: (2019)

Atractylenolide III inhibits epithelial-mesenchymal transition in small intestine epithelial cells by activating the AMPK signaling pathway
por: Huang, Mingjin, et al.
Publicado: (2022)

Atractylenolide-1 Targets FLT3 to Regulate PI3K/AKT/HIF1-α Pathway to Inhibit Osteogenic Differentiation of Human Valve Interstitial Cells
por: Wang, Jie, et al.
Publicado: (2022)

Atractylenolide-I Protects Human SH-SY5Y Cells from 1-Methyl-4-Phenylpyridinium-Induced Apoptotic Cell Death
por: More, Sandeep Vasant, et al.
Publicado: (2017)

Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-κB Signaling Pathway
por: Long, Fangyi, et al.
Publicado: (2020)

Atractylenolide II reverses the influence of lncRNA XIST/miR‐30a‐5p/ROR1 axis on chemo‐resistance of colorectal cancer cells
por: Zhang, Ruijuan, et al.
Publicado: (2019)

Atypical granular cell tumor of the urinary bladder: A case report
por: Wei, Ming-Ze, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2mkfg0khn29bjv1q9tqpvjn7op